Testing three drugs for advanced bile duct cancer
Part of Cancer clinical trials.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- Your performance status is good (ECOG score 0 to 1)
- You have confirmed advanced bile duct cancer (including gallbladder, intrahepatic, or extrahepatic cholangiocarcinoma)
- Your scans show late-stage disease (stage III/IV) and at least one measurable tumor spot
- Your liver function is suitable (Child-Pugh class A or B) and lab numbers are within set limits
- You can start and stay on the study safely for at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has grown despite previous treatment. The goal is to see if this new combination can help shrink tumors or slow down the cancer.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This trial tests a new combination of three drugs (anlotinib, nab-paclitaxel, and S-1) for people with advanced bile duct or gallbladder cancer that has progressed after first-line chemotherapy. The goal is to see if this combination can help control the cancer better than standard second-line options.
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.